Shortcuts

Daniel M. Junius

Retired President and Chief Executive Officer, ImmunoGen, Inc.

Independent Director

Age: 72

Director since:
March 2014

Committees:
Audit (Chair)
Finance

Other current public company director service:

  • GlycoMimetics, Inc. (since Mar. 2016)

Former public company director service:

  • ImmunoGen, Inc. (Nov. 2008 – Jun. 2018)
  • Vitae Pharmaceuticals, Inc. (Jul. 2016 – Oct. 2016)

Experience

ImmunoGen, Inc.

  • President and Chief Executive Officer (2009 – 2016)
  • President and Chief Operating Officer and Acting Chief Financial Officer (July 2008 - December 2008)
  • Executive Vice President and Chief Financial Officer (2006 – 2008)
  • Senior Vice President and Chief Financial Officer (2005 – 2006)


New England Business Service, Inc.

  • Executive Vice President and Chief Financial Officer (2002 – 2004)
  • Senior Vice President and Chief Financial Officer (1998 – 2002)


Nashua Corporation

  • Vice President and Chief Financial Officer (1996 – 1998)
  • Joined in 1984 and held various financial management positions of increasing responsibility

Qualifications

  • Financial Acumen: Extensive knowledge and experience in the review and preparation of financial statements and a strong understanding of complex financial and accounting topics, internal controls over financial reporting, and financial planning developed over the course of his almost twenty-five years serving in various financial management roles, including more than a decade as the chief financial officer of various companies.
  • Executive Leadership: Substantial executive leadership experience gained from serving as the Chief Executive Officer of ImmunoGen, Inc., a then public biotechnology company, which was acquired by AbbVie Inc. in February 2024, that developed targeted anticancer therapeutics, where he was credited with successfully building integrated research, clinical, regulatory and manufacturing functions at the company and expanding its technology portfolio significantly.
  • Corporate Strategy: Deep experience as displayed while at ImmunoGen, Inc., where under his leadership the company transformed from being a research-focused company to one with strong clinical development and manufacturing capabilities.
  • Mr. Junius also brings significant corporate governance, human capital management, innovation and R&D, operations, risk oversight and corporate finance skills and experience to the Board.

Education

  • BA, Political Science, Boston College